Premium
Flutamide‐induced regression of angiofibroma
Author(s) -
Gates George A.,
Rice Dale H.,
Koopmann Charles F.,
Schuller David E.
Publication year - 1992
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1288/00005537-199206000-00009
Subject(s) - juvenile nasopharyngeal angiofibroma , flutamide , testosterone (patch) , medicine , angiofibroma , hormone , urology , radiology , surgery , cancer , androgen receptor , prostate cancer
Juvenile nasopharyngeal angiofibroma (JNA) appears to be an endocrine‐responsive tumor. This concept was tested in five young men with JNA by treating them with a testosterone receptor blocker (flutamide) for 6 weeks preoperatively. Tumor size was evaluated by axial computed tomography both before and after flutamide therapy. Four of the five patients had an average tumor shrinkage of 44%. The patients tolerated the drug well, and the serum testosterone levels 2 or more years posttherapy were normal. This pilot study demonstrates that preoperative hormonal pharmacoreduction of JNA is a feasible adjunct to surgical therapy that offers the possibility of reduced blood loss. However, the authors believe that a formal clinical trial of this treatment approach is warranted and should be done before widespread adoption of this agent.